<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03950843</url>
  </required_header>
  <id_info>
    <org_study_id>125AF18022</org_study_id>
    <nct_id>NCT03950843</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo Control, Therapeutic Confirmatory, Phase III Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multi-center, Randomized, Double-blind, Placebo control, Therapeutic Confirmatory, Phase
      III Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean 24-hour heart rate(24-h mHR) compared with the baseline value</measure>
    <time_frame>at week 6 after first drug administration</time_frame>
    <description>To compare experimental group with placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in resting heart rate(HR) on 12-lead electrocardiogram(ECG) compared with the baseline value</measure>
    <time_frame>at week 2, week 4, week 6 and week 10 after first drug administration</time_frame>
    <description>To compare experimental group with placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of patients whose resting HR on 12-lead ECG achieved below 110 bpm at week 6 and week 10 among those with resting HR ≥ 110 bpm from baseline</measure>
    <time_frame>2 weeks, 4 weeks and 6 weeks and 10 weeks after first drug administration</time_frame>
    <description>To compare experimental group with placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of patients whose resting HR on 12-lead ECG achieved &lt; 80 bpm</measure>
    <time_frame>at week 6 and week 10 after first drug administration</time_frame>
    <description>To compare experimental group with placebo group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in modified EHRA score(European Heart Rhythm Association score of atrial fibrillation) compared with the baseline value</measure>
    <time_frame>at week 2, week 4, week 6 and week 10 after first drug administration</time_frame>
    <description>To compare experimental group with placebo group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group are treated with 1 capsule of CKD-825 and 2 placebo capsules(the placebo of CKD-825)
The necessity of a dose titration is adjudicated every 2 weeks.
After unblinding at the end of Administration Period, only patients in experimental group are treated with 1 capsule of CKD-825 for additional 4 weeks of Extension Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients assigned to this group are treated with 3 placebo capsules (the placebo of CKD-825)
The necessity of a dose titration is adjudicated every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-825</intervention_name>
    <description>Dosage Form: capsule
Dosage: 3 types(low/medium/high dose)
Frequency: QD(once daily) administration</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral capsule</intervention_name>
    <description>Placebo of CKD-825
Dosage Form: capsule
Dosage: NA
Frequency: QD administration</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Reference</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients aged ≥ 19 years with persistent or permanent Atrial Fibrillation

          -  Patients with modified EHRA(The European Heart Rhythm Association score of atrial
             fibrillation) score ≥ 2a

          -  Patients with resting HR ≥ 80 beats per minute(bpm)

          -  Patients with 24-h mHR ≥ 80 bpm on Holter ECG

        Exclusion Criteria:

          -  Treatment with antiarrhythmics within 2 weeks(Those who had washout period can be
             included)

          -  Pacemaker or implantable cardioverter defibrillator

          -  Catheter ablation for atrial fibrillation within 12 weeks before first investigational
             product(IP) administration

          -  Treatment for heart failure (New York Heart Association functional class 4)

          -  Myocardial infarction or unstable angina pectoris within 12 weeks before first IP
             administration

          -  Wolff-Parkinson-White syndrome

          -  Hepatic or renal disorder

          -  Systolic blood pressure &lt; 90 mmHg or diastolic blood pressure &lt; 60 mmHg

          -  Uncontrolled Diabetes(HbA1c &gt; 9%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaemin Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yongseog Oh, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JinBae Kim, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyunghee University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seongwook Han, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung Universtiy Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jongsung Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeonggeun On, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kee-Jun Choi, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sang-Weon Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sejong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyo-Seung Hwang, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moon Hyoung Lee, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Gu Shin, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nam-Ho Kim, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wonkwang University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae-Kyeong Jun, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Namgung, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daehyeok Kim, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyung Wook Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daein Lee, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chugbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hwan-Cheol Park, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eue-Keun Choi, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyung Suk Lee, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seon-a Jin, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jong-ll Choi, M.D, Ph.D</last_name>
    <phone>+82-2-2072-4164</phone>
    <email>stabler92@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jong-ll Choi</last_name>
    <phone>+82-2-2072-4164</phone>
    <email>stabler92@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jong-ll</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-ll Chio, M.D, Ph.D</last_name>
      <email>stabler92@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

